Community Research and Development Information Service - CORDIS


Worldwide there is a fast growing interest in the concept of Boron Neutron Capture Therapy (BNCT) as a potentially powerful tool for curing various forms of cancer. The method is especially targeted to tumours which are resistant to the more conventional methods of surgery, X-rays and chemotherapy. Practical realisation of BNCT must satisfy two major requirements. One is the development and availability of tumour affinic boron drugs and delivery mechanisms for different types of cancer. The other concerns the construction of neutron sources such as fast neutrons and gamma rays, which are capable of supplying a sufficient amount of thermal neutrons to the tumour region with a minimum of adventitious radiation. The only BNCT facility currently in use is installed at the TRIGA Mark 2 reactor of the Musashi Institute of Technology in Tokyo. It has become clear, however, that future BNCT facilities should use epithermal neutron beams to reach larger penetration depths. The purpose of this study is, therefore, to investigate the possibility of designing an epithermal BNCT facility at low power reactors with reasonable operating costs. TRIGA-type reactors are considered, a few of which are installed in university environments, where such a therapy facility requiring multi-disciplinary co-operation is most likely to be realised.

Additional information

Authors: RIEF H, JRC Ispra (IT);VAN HEUSDEN R, JRC Ispra (IT);PERLINI G, JRC Ispra (IT)
Bibliographic Reference: Paper presented: Workshop on New Clinical Applications and Neutron Sources for BNCT, Pavia (IT), June 13-14, 1991
Availability: Available from (1) as Paper EN 36889 ORA
Record Number: 199210819 / Last updated on: 1994-12-02
Original language: en
Available languages: en